TGRX-678 Chinese Phase II in Chronic Myelogenous Leukemia (CML) Patients
Recruiting now · Phase 2
Conditions studied: Chronic Myeloid Leukemia, Accelerated Phase CML
In brief
A Phase II study evaluating the safety and efficacy of TGRX-678 in Chronic Myelogenous Leukemia (CML) patients in Accelerated phase (AP) and are relapsed or refractory from third-generation Tyrosine Kinase Inhibitor (TKI) treatment
Key facts
- Study ID
- NCT06453902
- Run by
- Shenzhen TargetRx Co., Ltd.
- People needed
- 40
- Starts
- 2024-07-15
- Expected to finish
- 2028-04-30
- Last updated by the study team
- 2025-02-21
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Willing to consent
- 18 years of age or above at time of screening; both sexes eligible
- Relapsed or refactory from 3rd-generation Tyrosine kinase inhibitor (TKI) treatment
- For patients without T315I mutation, the patients must received 1st, 2nd and 3rd generation TKI
- For patients with T315I mutation, the patients much received Olverembatinib or Ponatinib treatment
- Diagnosis of CML-AP by bone marrow morphological test, molecular biology test or cytogenetic tests
- ECOG score </=2
- Minimum life expectancy of at least 3 months
- Adequate hematological indicators
- Adequate kidney function
- Adequate liver function
- Adequate coagulation function
- Adequate pancreatic function
- Adequate QTc interval as confirmed by electrocardiogram (ECG) test
- Negative pregnancy result at screening for female patients of child-bearing potential
- Willing to take contraceptive measure during the study (For male and female patients of child-bearing potential)
You may not qualify if…
- Reception of TKI treatment or presence of unrecovered TKI treatment related non-hematological adverse events within 7 days of first dose
- Reception of other anti-tumor treatments
- In need for immune suppressive treatment
- Usage of drugs associated with Torsades de Pointes within 1 months before screening
- Presence of other medical conditions that require using treatment that may have drug-drug interaction with the investigational drug
- History of hemapoietic stem cell transplant
- Presence of active central nervous system conditions
- CML-AP patients who already reached major hematological response
- CML-AP patients who used to progress to Blast Phase (BP)
- Presence or having uncontrolled condition for cardiovascular diseases
- History of any heart or cardiovascular conditions (except for patients with hypertension which is controlled by anti-hypertensive drugs, and blood pressure is controlled at no higher than 160/100 mmHg for 1 months before screening)
- Usage of any Traditional Chinese Medicine indicated for anti-tumor purpose 2 weeks before first dose
- Severe hemorrhagic disease unrelated to CML
- History of severe cardiovascular condition during past TKI treatment for CML
- History of pancreatic inflammation or alcohol abuse within 3 years before first dose
- Uncontrolled Hypertriglyceridemia
- Presence of malabsorption or other conditions that may affect drug absorption
- Diagnosis of other primary malignant tumor within 5 years
- Reception of major surgery 14 days before first dose
- Presence of continuous or active infection (including HIV, hepatitis B, hepatitis C)
- Presence of other conditions that the investigators or medical monitor deem unfit for the study
Where it is running
- Peking University People's Hospital — Beijing, Beijing Municipality, China (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.